First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations – JOURNAL OF THORACIC ONCOLOGY

Paz-Ares, LG; Ciuleanu, TE; Cobo, M; Bennouna, J; Schenker, M; Cheng, Y; Juan-Vidal, O; Mizutani, H; Lingua, A; Reyes-Cosmelli, F; Reinmuth, N; Menezes, J; Jassem, J; Protsenko, S; Richardet, E; Felip, E; Feeney, K; Zurawski, B; Alexandru, A; Jimenez, ED; Dakhil, S;...

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes – EUROPEAN JOURNAL OF CANCER

Reck, M; Ciuleanu, TE; Cobo, M; Schenker, M; Zurawski, B; Menezes, J; Richardet, E; Bennouna, J; Felip, E; Juan-Vidal, O; Alexandru, A; Cheng, Y; Sakai, H; Paz-Ares, L; Lu, S; John, T; Sun, XW; Moisei, A; Taylor, F; Lawrance, R; Zhang, XQ; Sylvester, J; Yuan, Y; Blum,...